

Dynorphin/Kappa Opioid Receptor Activity Within the Extended Amygdala Contributes to Stress-Enhanced Alcohol Drinking in Mice

Harold L. Haun, Christina L. Lebonville, Matthew G. Solomon, William C. Griffin, Marcelo F. Lopez, and Howard C. Becker

ABSTRACT

BACKGROUND: While there is high comorbidity of stress-related disorders and alcohol use disorder, few effective treatments are available and elucidating underlying neurobiological mechanisms has been hampered by a general lack of reliable animal models. Here, we use a novel mouse model demonstrating robust and reproducible stress-enhanced alcohol drinking to examine the role of dynorphin/kappa opioid receptor (DYN/KOR) activity within the extended amygdala in mediating this stress-alcohol interaction.

METHODS: Mice received repeated weekly cycles of chronic intermittent ethanol exposure alternating with weekly drinking sessions \pm forced swim stress exposure. *Pdyn* messenger RNA expression was measured in the central amygdala (CeA), and DYN-expressing CeA neurons were then targeted for chemogenetic inhibition. Finally, a KOR antagonist was microinjected into the CeA or bed nucleus of the stria terminalis to examine the role of KOR signaling in promoting stress-enhanced drinking.

RESULTS: Stress (forced swim stress) selectively increased alcohol drinking in mice with a history of chronic intermittent ethanol exposure, and this was accompanied by elevated *Pdyn* messenger RNA levels in the CeA. Targeted chemogenetic silencing of DYN-expressing CeA neurons blocked stress-enhanced drinking, and KOR antagonism in the CeA or bed nucleus of the stria terminalis significantly reduced stress-induced elevated alcohol consumption without altering moderate intake in control mice.

CONCLUSIONS: Using a novel and robust model of stress-enhanced alcohol drinking, a significant role for DYN/KOR activity within extended amygdala circuitry in mediating this effect was demonstrated, thereby providing further evidence that the DYN/KOR system may be a valuable target in the development of more effective treatments for individuals presenting with comorbidity of stress-related disorders and alcohol use disorder.

<https://doi.org/10.1016/j.biopsych.2022.01.002>

Stress is commonly regarded as a potent trigger for relapse and a significant factor in promoting excessive alcohol (ethanol) drinking (1–3). There is a high comorbidity between stress-related disorders, including depression, anxiety disorders, and posttraumatic stress disorder, and alcohol use disorder (AUD) (4–8). The prevalence and magnitude of the problem underscores the importance of understanding mechanisms underlying the influence of stress on alcohol use, which is essential for developing new and more effective treatment strategies for individuals with coexisting stress and AUD.

Stress and alcohol exposure influence overlapping systems and neural circuits in the brain, producing adaptations that compromise the ability of individuals to engage in behavioral flexibility that would enhance control over alcohol consumption as well as appropriately respond to stressful events that may provoke return to excessive drinking (9,10). Despite significant advances in our understanding about how stress and alcohol alter brain function, the mechanisms and neurocircuits

underlying the complex interactions between stress and alcohol consumption are not fully understood (11). Indeed, demonstrating reliable and consistent effects related to the interaction between stress and alcohol drinking in animal models has been challenging (12–14). The general lack of reliable preclinical models has, at least in part, impeded progress toward developing effective therapeutics that especially target stress-related excessive drinking.

To address this shortcoming, we developed a mouse model wherein repeated brief forced swim stress (FSS) exposure interacts with chronic intermittent ethanol (CIE) exposure to enhance alcohol drinking in dependent (CIE-exposed) mice but not alter more moderate stable intake in nondependent mice (15,16). Corroborating an earlier study in rats (17), this stress-enhanced drinking in CIE-exposed mice is robust and reproducible, having been demonstrated by other research groups as well (18–20). Increased drinking in mice with a history of both chronic alcohol exposure and stress experience provides an ideal opportunity to use this

SEE COMMENTARY ON PAGE 1000

CIE-FSS drinking model to probe mechanisms and potential targets relevant to the problem of stress-related excessive alcohol drinking.

Because both stress and chronic alcohol engage the dynorphin/kappa opioid receptor (DYN/KOR) system, the role of this neuropeptide system in chronic alcohol-related dysphoria and elevated drinking has gained increasing attention (21–23). DYNs are peptides derived from the precursor Pdyn (prodynorphin) that preferentially bind to KORs, producing physiological and behavioral effects via inhibitory G-protein coupling and other signaling cascades (24–27). KOR activation has been shown to produce aversive/dysphoric effects as indicated by measures of conditioned avoidance and anxiety-like and depression-like behavior (28,29). Stress exposure activates the DYN/KOR system, eliciting dysphoria and anxiety-like behaviors (30) along with elevated DYN immunoreactivity in brain regions that are integral to reward and stress circuitries involved in alcohol/drug addiction (31).

Pharmacological manipulation of DYN/KOR activity has been shown to alter behavioral responses to stress and motivational effects of alcohol in a variety of experimental conditions (22,32). Systemic administration of KOR antagonists has been shown to reduce high levels of alcohol consumption associated with dependence and binge-drinking models in rats (33,34) and mice (20,35,36). Evidence points to involvement of the extended amygdala in mediating these effects. Interconnected brain structures comprising extended amygdala circuitry, including the nucleus accumbens, central amygdala (CeA), and bed nucleus of the stria terminalis (BNST), are rich in DYN and KOR and highly responsive to stress and chronic alcohol exposure (37–41). Direct infusion of the KOR antagonist norbinaltorphimine (norBNI) into these structures reduces excessive alcohol drinking in models of dependence (42–44) and binge-like drinking (35,45). While we recently demonstrated that systemic administration of a KOR antagonist can block the ability of stress to enhance alcohol consumption (36), the site of action mediating this effect is not known.

This series of studies was designed to probe the role of DYN/KOR activity in two prominent structures within extended amygdala circuitry (CeA and BNST) as it relates to stress-enhanced alcohol drinking. Specifically, our CIE-FSS drinking model was used to 1) examine how a history of CIE and FSS exposure, alone and in combination, affects expression of *Pdyn* messenger RNA (mRNA) within the CeA; 2) determine the effect of targeted chemogenetic silencing of DYN-expressing neurons within the CeA (CeA^{DYN} neurons) on stress-enhanced alcohol drinking; and 3) determine the contribution of KOR signaling within the CeA and BNST in mediating the ability of stress to further enhance elevated alcohol consumption associated with dependence. Results from these studies provide critical evidence indicating that a history of chronic alcohol exposure and stress engage the DYN/KOR system within the extended amygdala in mediating stress-enhanced drinking. As such, these findings support recent clinical efforts devoted to evaluating the therapeutic value of targeting this neuropeptide system in reducing heavy drinking in individuals comorbid with stress-related disorders and AUD (46).

METHODS AND MATERIALS

A detailed description of all experimental procedures, including the CIE-FSS drinking model, assays for *Pdyn* mRNA measurement, stereotaxic surgery, virus and drug infusions, histology, and drug preparations, is provided in the [Supplement](#).

CIE and FSS Drinking Model

All studies involved use of adult male C57BL/6J mice and *Pdyn-IRES-Cre* mice (35,47) treated in the CIE-FSS drinking model as previously described (15,16,36). Briefly, after establishing stable 1-hour daily ethanol (15% vol/vol) intake, mice were separated into four groups: control (CTL), CIE-alone, FSS-alone, and CIE+FSS. Mice received CIE vapor or air exposure in inhalation chambers followed by test drinking sessions for 5 consecutive days. This pattern of weekly CIE (or air) exposure alternating with weekly test drinking sessions was repeated for three or four cycles (Figure 1). Mice in the FSS-alone and CIE+FSS groups experienced brief (10 min) FSS exposure 4 hours prior to each of the test drinking sessions. The remaining nonstressed mice (CTL and CIE groups) were left in their home cage undisturbed.

Study Procedures

Effects of CIE and FSS Exposure on *Pdyn* mRNA Expression in the CeA. C57BL/6J mice treated in the CIE-FSS drinking model were sacrificed on the final day of test 4 at 30 minutes, 4 hours, or 24 hours after FSS exposure (or at equivalent times for no-stress groups) ($n = 6–10$ /group/time point). Collection of CeA samples, RNA extraction, and Taqman quantitative reverse transcription polymerase chain reaction assays were performed as previously described (48,49).

Effect of Chemogenetic Inhibition of DYN-Expressing Neurons in the CeA on Alcohol Drinking in the CIE-FSS Model. Adult male *Pdyn-IRES-Cre* mice received bilateral infusions of a Cre-dependent virus containing an inhibitory DREADD (designer receptor exclusively activated by designer drugs) (AAV8-hSyn-DIO-hM4Di-mCherry) ($n = 10$ or 11/group) or control virus (AAV8-hSyn-DIO-mCherry) ($n = 6$ or 7/group) into the CeA to target CeA^{DYN} neurons as previously described (35). After at least 2 weeks of recovery, the baseline phase of the study commenced. On day 2 and day 4 of test 3, mice were injected intraperitoneally with vehicle (0.9% saline) or clozapine N-oxide (CNO) (3 mg/kg) to activate the DREADD. The order of drug administration was counterbalanced for each group.

Effect of KOR Antagonism in the CeA or BNST on Alcohol Drinking in the CIE-FSS Model. C57BL/6J mice received bilateral guide cannula positioned above the CeA ($n = 7–9$ /group) or BNST ($n = 8–10$ /group) (35,45). After at least 2 weeks of recovery, baseline drinking commenced. At 16 hours prior to the start of the drinking session on day 3 of test 3, separate groups of mice in each experimental condition received microinjection of the KOR antagonist norBNI (2.5 μ g/side) or vehicle (1 \times phosphate-buffered saline) into the CeA or BNST.




Figure 1. CIE-FSS drinking model. Mice were treated in the CIE-FSS drinking model involving weekly CIE or air exposure cycles alternating with weekly test drinking sessions (1 hour) with or without FSS exposure (10 min; 4 hours prior to each drinking session). Solid circles represent daily 1-hour drinking sessions. After establishing stable baseline drinking over 4 weeks, mice were separated into four groups: CTL, CIE-alone, FSS-alone, and CIE+FSS groups. Weekly CIE/air exposures alternated with weekly (5 days) test drinking sessions for several cycles. CIE, chronic intermittent ethanol; CTL, control; EtOH, ethanol; FSS, forced swim stress.

Statistical Analysis

Alcohol intake (g/kg) was analyzed by analysis of variance (ANOVA), with group (CTL, CIE, FSS, CIE+FSS) as a between-subjects factor and test cycle (average weekly intake for baseline and tests 1–4) as a repeated measure. *Pdyn* mRNA expression in the CeA was expressed as a fold change from the CTL condition and analyzed at each time point by ANOVA, with group as the main factor. For the chemogenetic study, alcohol intake and change in intake relative to vehicle was analyzed by ANOVA, with group and virus as between-subject variables and drug (CNO vs. saline) as a repeated measure. For microinjection studies, ANOVAs included group and drug (norBNI vs. vehicle) as between-subject variables and day as a repeated measure in analyses of alcohol consumption (average of days 3 and 4) and difference in intake from respective vehicle group. When appropriate, significant main effects and interactions were further analyzed using Newman-Keuls post hoc comparisons. In chemogenetic and pharmacological studies, only data from subjects in which targeted viral expression or placement of microinjectors were verified as correct were used in analyses.

RESULTS

Combined CIE and Stress (FSS) Exposure Increases *Pdyn* mRNA Expression in the CeA

While alcohol consumption remained relatively stable over successive test cycles in the FSS-alone and CTL groups, intake increased above baseline levels in the CIE-exposed groups, with this effect most robust in the CIE+FSS group (Figure 2A, B). This was supported by a significant group × test cycle interaction ($F_{12,352} = 5.942, p < .001$), which revealed a modest increase in alcohol consumption in the CIE-alone group, with intake during test 2 and test 4 greater than baseline ($ps < .05$). Alcohol intake in the CIE+FSS group was greater during all test weeks compared with their baseline level

of intake ($ps < .001$), and drinking was greater during each test week in the CIE+FSS condition compared with the CIE-alone group ($ps < .05$). Separate analysis of alcohol intake during the final test period prior to sacrifice (test 4) revealed a main effect of group ($F_{3,88} = 13.025, p < .001$). While alcohol intake for CIE-alone and FSS-alone groups did not significantly differ from the CTL group, CIE+FSS mice exhibited greater alcohol intake than all other groups ($ps < .001$) (Figure 2C). These results confirm our previous findings that FSS experience selectively enhances alcohol drinking in dependent (CIE-exposed) mice while not altering intake in nondependent (FSS-alone) mice (15,16,36).

Analysis of *Pdyn* mRNA expression in the CeA at the end of test 4 revealed main effects of group at 30 minutes ($F_{3,30} = 7.055, p < .001$) and 4 hours ($F_{3,23} = 3.33, p = .037$) following the last FSS exposure but not at 24 hours after FSS ($F_{3,27} = 0.415, p = .744$). Post hoc analyses showed that *Pdyn* mRNA expression was selectively elevated in the CIE+FSS group relative to the CTL group at 30 minutes and 4 hours after FSS exposure, with values normalizing at the 24-hour time point (Figure 2D). Neither CIE-alone nor FSS-alone treatments produced an increase in *Pdyn* mRNA levels in the CeA. Schematic depiction of bilateral tissue punches collected from the CeA is shown in Figure 2E.

Chemogenetic Inhibition of CeA^{DYN} Neurons Reduces Stress (FSS)-Enhanced Alcohol Drinking in CIE-Exposed *Pdyn-IRES-Cre* Mice

Pdyn-IRES-Cre mice were used to target expression of an inhibitory (hM4Di) DREADD or control virus in CeA^{DYN} neurons (Figure 3A). Using this same strategy, we previously demonstrated fidelity of expression and functionality of this viral vector (35). In this study, expression of the mCherry marker was confined to the CeA (Figure 3B).

Information on average weekly alcohol intake prior to administering CNO during test 3 is provided in Table 1. ANOVA




Figure 2. A history of CIE+FSS exposure increases *Pdyn* mRNA expression in the CeA. **(A)** Mice were sacrificed, and brain tissue was collected at 30 minutes, 4 hours, or 24 hours following the last FSS exposure during test 4 (denoted by green star) to assess *Pdyn* mRNA expression in the CeA (purple triangles denote FSS exposures) ($n = 6\text{--}10/\text{group}/\text{time point}$). **(B)** Average weekly alcohol consumption across each phase of the study. Alcohol intake increased compared with baseline in the CIE-alone group during test 2 and test 4 ($+ps < .05$); alcohol drinking in the CIE+FSS group was significantly greater during each of the test cycles compared with baseline ($*ps < .05$) and compared with the CIE-alone group during test cycles did not differ from baseline levels. **(C)** Average alcohol consumption during test 4. Alcohol intake was greater in the CIE+FSS group than in all other groups, which did not significantly differ from each other ($\#ps < .001$). **(D)** *Pdyn* mRNA expression in the CeA was significantly elevated in CIE+FSS compared with CTL mice at 30 minutes ($*p < .01$) and 4 hours ($*p < .05$) after FSS exposure at the end of test 4, returning to CTL levels at 24 hours. All values are mean \pm SEM. **(E)** Schematic representation of tissue punches collected from the CeA. CeA, central amygdala; CIE, chronic intermittent ethanol; CTL, control; FSS, forced swim stress; mRNA, messenger RNA.

revealed a main effect of group ($F_{3,60} = 8.397, p < .001$) and test cycle ($F_{2,120} = 22.632, p < .001$) but no effect of virus ($F_{1,60} = 1.895, p = .174$), indicating that viral expression did not influence alcohol drinking prior to testing. A group \times test cycle interaction ($F_{6,120} = 6.258, p < .001$) was observed, and post hoc analyses revealed increased alcohol intake in the CIE-alone and CIE+FSS groups during test 1 and test 2 compared with their respective baseline levels of intake ($ps < .05$).

Analysis of alcohol intake during test 3 indicated a marginally significant group \times virus \times drug interaction ($F_{3,60} = 2.340, p = .082$). Separate analysis of alcohol intake in mice expressing hM4Di in CeA^{DYN} neurons revealed a significant group \times drug interaction ($F_{3,38} = 8.521, p < .001$). Following vehicle (saline) administration, mice with a history of CIE alone and CIE+FSS consumed more alcohol than CTL mice that received vehicle ($ps < .05$). Furthermore, alcohol intake was significantly greater in the CIE+FSS group than in the CIE-alone condition ($p < .005$), whereas FSS alone did not significantly alter alcohol consumption. Selective silencing of CeA^{DYN} neurons following CNO injection resulted in significant reduction in alcohol intake in the CIE+FSS group ($p < .001$). CNO injection produced a marginal reduction in drinking in the CIE-alone group ($p = .082$) but did not alter alcohol intake in the FSS-alone or CTL groups (Figure 3C). Similar

analysis of alcohol consumption in mice treated with control virus indicated a main effect of group ($F_{3,22} = 16.14, p < .001$) but no group \times drug interaction ($F_{3,22} = 0.128, p = .381$). As expected, alcohol intake was significantly greater in CIE-alone mice than CTL mice ($p < .05$), and stress further enhanced this elevated drinking (CIE+FSS $>$ CIE-alone) ($p < .01$). Alcohol intake in the FSS-alone group did not differ from the CTL group. CNO injection in mice that harbored the control virus did not alter alcohol drinking in any of the groups (Figure 3D).

To further examine the apparent selective effect of CNO in mice treated with the active (hM4Di-containing) virus, data expressed as a change from the vehicle (saline) condition for each subject were analyzed (Figure 3E). Post hoc analysis of the group \times virus interaction ($F_{3,60} = 2.34, p < .05$) indicated that CNO injection significantly reduced alcohol intake (relative to vehicle) only in CIE+FSS mice that harbored active versus control virus ($p < .001$), and this reduction was greater in CIE+FSS mice compared with all other groups that were treated with active virus (p values $< .01$). Thus, inactivation of CeA^{DYN} neurons following CNO injection significantly attenuated the ability of stress (FSS) to further enhance alcohol consumption in CIE-exposed mice, and this effect was only observed in mice treated with the inhibitory (hM4Di) DREADD-containing virus.




Figure 3. Chemogenetic inhibition of CeA^{DYN} neurons attenuates stress-enhanced alcohol drinking. **(A)** For targeted expression of an inhibitory DREADD, *Pdyn-IRES-Cre* mice were bilaterally infused with AAV8-hSyn-DIO-hM4Di-mCherry or AAV8-hSyn-DIO-mCherry into the CeA 2 weeks prior to start of baseline drinking; vehicle or CNO (3 mg/kg) was injected 30 minutes prior to the second and fourth drinking sessions during test 3 in a balanced crossover design (denoted by green arrows). **(B)** Viral expression was localized to the CeA as indicated by visualization of mCherry fluorescence. **(C)** Average alcohol intake in mice expressing hM4Di-containing virus ($n = 10$ or 11 /group). In vehicle-treated mice, alcohol consumption was greater in CIE-alone and CIE+FSS groups than in CTL and FSS-alone groups, which did not differ ($^*p < .05$). In addition, intake following vehicle injection was greater in CIE+FSS mice than in CIE-alone mice ($^*p < .005$). Activation of the inhibitory DREADD expressed in CeA^{DYN} neurons via CNO injection resulted in a significant reduction in alcohol intake in the CIE+FSS group compared with those mice receiving vehicle ($^*p < .001$). **(D)** Average alcohol intake in mice treated with control virus ($n = 6$ or 7 /group). Vehicle injection resulted in the expected greater alcohol intake in CIE-alone and CIE+FSS groups compared with the other groups ($^*ps < .05$), and intake was greater in the CIE+FSS mice than in CIE-alone mice ($^*p < .005$). CNO injection did not alter alcohol drinking in any group relative to when those mice received vehicle injection. **(E)** Change from respective vehicle alcohol intake across treatment and virus groups. CNO injection significantly reduced alcohol intake (relative to vehicle) in CIE+FSS mice that harbored active vs. control virus ($^*p < .001$), and this reduction was greater in CIE+FSS mice compared with when CNO was injected in CIE-alone, FSS-alone, and CTL groups that were treated with active virus ($^*ps < .01$). All values are mean \pm SEM. AP, anteroposterior; BLA, basolateral amygdala; CeA, central amygdala; CIE, chronic intermittent ethanol; CNO, clozapine N-oxide; CTL; control; D, dorsal; DREADD; designer receptor exclusively activated by designer drugs; DYN, dynorphin; FSS, forced swim stress; L, lateral; LA, lateral amygdala; M, medial; V, ventral; VEH, vehicle.

Table 1. Average Weekly Alcohol Intake Prior to Chemogenetic Inhibition of CeA^{DYN} Neurons

AAV	Group	Baseline	Test 1	Test 2
hM4Di	CTL	1.48 \pm 0.12	1.44 \pm 0.14	1.49 \pm 0.16
	FSS	1.57 \pm 0.13	1.78 \pm 0.12	1.94 \pm 0.17
	CIE	1.49 \pm 0.18	1.95 \pm 0.26 ^a	1.84 \pm 0.20 ^a
	CIE+FSS	1.54 \pm 0.15	2.13 \pm 0.25 ^a	2.54 \pm 0.22 ^a
mCherry	CTL	1.62 \pm 0.17	1.72 \pm 0.17	1.33 \pm 0.13
	FSS	1.49 \pm 0.11	1.56 \pm 0.19	1.65 \pm 0.06
	CIE	1.61 \pm 0.11	2.53 \pm 0.19 ^a	2.37 \pm 0.20 ^a
	CIE+FSS	1.73 \pm 0.13	2.83 \pm 0.34 ^a	2.57 \pm 0.32 ^a

Alcohol intake (g/kg) in mice expressing hM4Di or mCherry in CeA^{DYN} neurons during baseline and test weeks prior to challenge with vehicle or CNO (3 mg/kg) during test 3. Values are mean \pm SEM.

AAV, adeno-associated virus; CeA^{DYN}, dynorphin-expressing central amygdala; CIE, chronic intermittent ethanol; CNO, clozapine N-oxide; CTL, control; FSS, forced swim stress.

^aDiffers from respective baseline levels ($p < .05$).

Intra-CeA Injection of a KOR Antagonist Blocks Stress Enhancement of Alcohol Drinking in CIE-Exposed Mice

Alcohol intake prior to microinjection of the KOR antagonist during test 3 is shown in Table 2. ANOVA indicated significant main effects of group ($F_{3,64} = 14.823, p < .001$) and test cycle ($F_{2,128} = 75.339, p < .001$) and a group \times test cycle interaction ($F_{6,128} = 12.882, p < .001$). Post hoc analyses indicated that alcohol intake in the CIE-alone and CIE+FSS groups during test 1 and test 2 was greater than their respective baseline levels of intake ($p < .05$). In contrast, FSS alone did not alter alcohol drinking in nondependent mice.

Microinjection of norBNI into the CeA during test 3 (Figure 4A, B) selectively attenuated elevated drinking in mice with a history of CIE alone and CIE+FSS without affecting more moderate levels of consumption in FSS-alone and CTL groups (Figure 4C). This finding is supported by analysis of average alcohol intake during the 2 days following vehicle or norBNI microinjection, which revealed a significant group \times drug interaction ($F_{3,60} = 6.742, p < .001$). Post hoc analyses showed that vehicle-treated mice with a history of CIE alone and CIE+FSS exposure consumed more alcohol than CTL mice (p values $< .005$) and, replicating our earlier finding, alcohol intake was significantly greater in CIE+FSS compared with CIE-alone mice ($p < .05$). Microinjection of norBNI reversed elevated alcohol intake in both CIE-alone and CIE+FSS groups ($p < .01$). Analysis of daily alcohol intake during test 3 revealed a similar profile of results (Figure S2A, B). To evaluate the relative magnitude of the norBNI effect across all groups, data were also analyzed as a difference from the average vehicle intake for each group. ANOVA revealed a significant group \times drug interaction ($F_{3,60} = 6.742, p < .001$), and post hoc analysis indicated that while a trend was apparent in the CIE-alone group ($p = .125$), norBNI significantly reduced alcohol intake relative to the respective vehicle condition only in the CIE+FSS group ($p < .001$). Furthermore, the reduction in alcohol drinking following intra-CeA norBNI injection (relative to vehicle) was significantly greater in the CIE+FSS group compared with all other groups, which did not differ from each other ($p < .01$) (Figure 4D). Collectively, these results suggest that blocking KOR signaling in the CeA was especially effective in reducing stress-enhanced drinking in the model. Schematic representation of injection sites for mice

Table 2. Average Weekly Alcohol Intake Prior to Injection of KOR Antagonist Into CeA

Group	Baseline	Test 1	Test 2
CTL	1.88 \pm 0.07	2.19 \pm 0.09	1.89 \pm 0.08
FSS	1.90 \pm 0.08	2.37 \pm 0.15	2.03 \pm 0.12
CIE	1.88 \pm 0.08	2.82 \pm 0.11 ^a	2.94 \pm 0.16 ^a
CIE+FSS	1.82 \pm 0.08	3.04 \pm 0.14 ^a	3.08 \pm 0.14 ^a

Alcohol intake (g/kg) in mice during baseline and test weeks prior to bilateral microinjection of vehicle or norBNI (2.5 μ g/side) into the CeA during test 3. Values are mean \pm SEM.

CeA, central amygdala; CIE, chronic intermittent ethanol; CTL, control; FSS, forced swim stress; KOR, kappa opioid receptor; norBNI, norbinaltorphimine.

^aDiffers from respective baseline levels ($p < .05$).

that received vehicle or norBNI into the CeA is shown in Figure S3A and B, respectively.


Intra-BNST Injection of a KOR Antagonist Blocks Stress Enhancement of Alcohol Drinking in CIE-Exposed Mice

Given our previous work showing that KOR antagonism in the BNST reduced heavy (binge-like) alcohol drinking (45) and that dynorphinergic neurons in the CeA project to the BNST (40,50), this study was conducted to examine whether blocking KOR signaling in the BNST attenuates the ability of stress to further enhance elevated drinking in CIE-exposed mice. As in previous experiments, alcohol consumption increased over baseline levels during test 1 and test 2 in the CIE-alone and CIE+FSS groups, while intake remained relatively stable for the FSS-alone and CTL groups (Table 3). This was supported by significant main effects of group ($F_{3,68} = 13.527, p < .001$) and test cycle ($F_{2,136} = 21.644, p < .001$) and the group \times test cycle interaction ($F_{6,136} = 9.009, p < .001$).

Intra-BNST norBNI administration during test 3 (Figure 5A, B) reduced elevated alcohol intake in the CIE-alone and CIE+FSS groups without altering moderate intake in the FSS-alone and CTL groups (Figure 5C). Analysis of average intake during the 2 days after microinjection revealed a group \times drug interaction ($F_{3,64} = 3.975, p = .012$). Post hoc analyses showed that alcohol intake following vehicle administration was significantly greater in CIE+FSS mice compared with the CIE-alone group ($p < .01$), and both groups consumed more alcohol than FSS-alone and CTL mice ($p < .001$), which did not significantly differ from each other. Microinjection of norBNI into the BNST significantly reduced elevated alcohol consumption in the CIE-alone ($p < .005$) and CIE+FSS ($p < .001$) groups. Analysis of daily alcohol intake during test 3 produced a similar profile of results (Figure S4A, B). Analysis of the difference in alcohol intake following intra-BNST norBNI injection relative to the appropriate average vehicle intake for each group revealed a significant group \times drug interaction ($F_{3,64} = 3.975, p < .01$). While intra-BNST norBNI reduced alcohol drinking (relative to vehicle levels) in the CIE-alone group ($p = .024$) and CIE+FSS mice ($p < .001$), this effect was significantly more robust in the CIE+FSS group compared with all other groups, including CIE-alone mice ($p < .05$) (Figure 5D). In contrast, norBNI injection into the BNST did not alter alcohol intake in the FSS-alone or CTL groups. Schematic representation of injection sites for mice that received vehicle or norBNI into the BNST is shown in Figure S5A and B, respectively.

DISCUSSION

Our studies validate the CIE-FSS drinking paradigm as a framework for modeling stress-enhanced alcohol drinking and demonstrate the significant contribution of DYN/KOR activity within the extended amygdala in mediating this behavior. A history of repeated FSS in CIE-exposed mice resulted in escalation of voluntary alcohol consumption, and this was accompanied by elevated *Pdyn* mRNA expression in the CeA. Targeted chemogenetic silencing of DYN-containing neurons in the CeA completely blocked the ability of stress to enhance alcohol drinking in the model. Furthermore, pharmacological



CIE+FSS group compared with all other groups, which did not differ from each other (^{##}*p* < .01). CeA, central amygdala; CIE, chronic intermittent ethanol; CTL, control; FSS, forced swim stress; norBNI, nornalatorphimine.

blockade of KOR within the CeA or BNST normalized drinking in mice with a history of both stress and CIE exposure. Together, these data suggest that CeA^{DYN} neurons are uniquely responsive to a history of chronic alcohol exposure and stress, and KOR signaling within the CeA and BNST plays an important role in mediating stress-enhanced alcohol drinking.

While chronic alcohol exposure and stress are known to produce dynamic alterations in brain gene expression (51–55), only recently have genomic changes in relation to stress-alcohol interactions been explored (18). This latter study revealed both unique transitory and long-lasting changes in gene expression in the prefrontal cortex associated with stress-enhanced alcohol consumption in the CIE-FSS drinking model. In this study, we show that *Pdyn* mRNA levels in the CeA are elevated at 30 minutes and 4 hours after FSS exposure only in mice with a history of both FSS and CIE exposure. This change was not observed in other groups (CIE-alone and FSS-alone conditions) that did not exhibit increased alcohol intake relative to the CTL condition. Studies in rats have shown

Table 3. Average Weekly Alcohol Intake Prior to Injection of KOR Antagonist Into BNST

Group	Baseline	Test 1	Test 2
CTL	1.97 ± 0.12	1.85 ± 0.12	1.84 ± 0.15
FSS	2.02 ± 0.19	2.18 ± 0.12	2.02 ± 0.16
CIE	2.13 ± 0.13	2.84 ± 0.13 ^a	2.99 ± 0.16 ^a
CIE+FSS	1.99 ± 0.12	2.88 ± 0.12 ^a	2.93 ± 0.15 ^a

Alcohol intake (g/kg) in mice during baseline and test weeks prior to bilateral microinjection of vehicle of norBNI (2.5 μg/side) into the BNST during test 3. Values are mean ± SEM.

BNST, bed nucleus of the stria terminalis; CIE, chronic intermittent ethanol; CTL, control; FSS, forced swim stress; norBNI, nornalatorphimine.

^aDiffers from respective baseline levels (*p* < .05).

Figure 4. Microinjection of norBNI into the CeA attenuates stress-enhanced alcohol drinking. (A) Guide cannulae were implanted over the CeA 2 weeks prior to the start of baseline drinking; vehicle or norBNI (2.5 μg/side) was infused 16 hours prior to the third drinking session during test 3 (denoted by green arrow). (B) Schematic representation of stereotaxic bilateral placement of guide cannulae over the CeA. (C) Average alcohol intake (over day 3 and day 4) in mice receiving vehicle (*n* = 7–9/group) or norBNI (*n* = 8 or 9/group) injection in the CeA. Vehicle-treated CIE-alone and CIE+FSS groups consumed significantly more alcohol than CTL and FSS-alone groups (which did not differ) (^{*}*p* < .05), and alcohol intake was greater in CIE+FSS than in CIE-alone mice (^{*}*p* < .05); norBNI treatment blocked elevated drinking in CIE-alone ([#]*p* < .01) and CIE+FSS (^{##}*p* < .001) groups without altering intake in the FSS-alone or CTL groups. (D) Difference from respective vehicle alcohol intake across treatment groups. Intra-CeA norBNI injection significantly reduced alcohol intake (relative to vehicle) only in the CIE+FSS group (^{***}*p* < .001), and this effect was significantly greater in the

an upregulation in *Pdyn* mRNA expression in the CeA following chronic alcohol drinking (56) and acute withdrawal from CIE exposure (43). FSS experience also has been reported to increase *Pdyn* mRNA levels in extended amygdala structures (57,58). Together, these findings indicate that the CeA is highly responsive to stress and chronic alcohol exposure, and changes in *Pdyn* transcriptional activity may contribute to enhanced motivation to drink following combined stress and chronic alcohol exposure.

The CeA is a key structure within extended amygdala circuitry with rich expression of both DYN and KORs (38–40). In this study, using a validated transgenic mouse model (47) along with a validated DREADD-containing viral construct (35), targeted chemogenetic inactivation of CeA^{DYN} neurons blocked stress-enhanced alcohol drinking. Vehicle injections in mice expressing the inhibitory (hM4Di) DREADD did not alter alcohol drinking, and reduced alcohol intake in mice injected with CNO is not likely to be attributed to off-target effects of CNO because the ligand did not alter alcohol consumption in mice that received control virus treatment. Using a similar experimental strategy, silencing CeA^{DYN} neurons was shown to significantly reduce alcohol consumption in a binge-drinking model (35). Likewise, genetic deletion of *Pdyn* in the CeA reduced alcohol drinking in models of high intake (38). Together, these data indicate that dynorphinergic activity in the CeA plays a significant role in regulating alcohol consumption, including elevated drinking associated with stress.

CeA^{DYN} neurons produce effects through signaling at KORs locally within the CeA as well as in several projection regions. Studies have shown that the KOR antagonism within the CeA and other extended amygdala structures (e.g., BNST) reduces alcohol drinking (35,42,43,45), and this is congruent with findings showing that systemic administration of KOR antagonists reduces alcohol consumption in a variety of models (20,22,33–36). Results from this study indicate that direct injection of the KOR antagonist norBNI into the CeA or BNST




Figure 5. Microinjection of norBNI into the BNST attenuates stress-enhanced alcohol drinking. **(A)** Guide cannulae were implanted over the BNST 2 weeks prior to the start of baseline drinking; vehicle or norBNI (2.5 μ g/side) was infused 16 hours prior to the third drinking session during test 3 (denoted by green arrow). **(B)** Schematic representation of stereotaxic bilateral placement of guide cannulae over the BNST. **(C)** Average alcohol intake (over day 3 and day 4) in mice receiving vehicle ($n = 8-10$ /group) or norBNI ($n = 8-10$ /group) injection in the BNST. Following vehicle injection, CIE+FSS mice consumed significantly more alcohol than the CIE-alone group ($^*p < .05$), and both CIE+FSS and CIE-alone groups consumed more alcohol than CTL and FSS-alone groups (which did not differ) ($^*ps < .05$); norBNI treatment blocked elevated drinking in CIE-alone ($^*p < .005$) and CIE+FSS ($^{##}p < .001$) groups without altering intake in the FSS-alone or CTL groups. **(D)** Difference from respective vehicle alcohol intake across treatment groups. Intra-BNST norBNI injection significantly reduced alcohol intake (relative to vehicle) in the CIE-alone group ($^*p < .05$) and the CIE+FSS group ($^{***}p < .001$), and this effect was significantly greater in the CIE+FSS group

compared with all other groups, which did not differ from each other ($^{\#}ps < .05$). BNST, bed nucleus of the stria; CIE, chronic intermittent ethanol; CTL, control; FSS, forced swim stress; norBNI, norbinaltorphimine.

blocked the ability of stress to enhance voluntary alcohol drinking in the CIE+FSS group. Thus, these are the first data to directly implicate a role for DYN/KOR activity within extended amygdala circuitry in contributing to stress-induced excessive drinking. While there is evidence for dynorphinergic projections from the CeA to the BNST (40,50), the extent to which these results are mediated by KOR signaling within the CeA and other projection sites, including the BNST, will require more direct circuitry-based examination.

CeA^{DYN} neurons are primarily GABAergic (gamma-aminobutyric acid) and known to coexpress other neuropeptides that influence alcohol drinking, such as corticotropin release factor and neurotensin (59,60). Thus, co-release of GABA (gamma-aminobutyric acid) and other peptides may contribute to stress-enhanced drinking in this model, and this possibility cannot be ruled out. However, results from our chemogenetic and pharmacological studies strongly implicate a significant role for engagement of DYN/KOR activity within extended amygdala circuitry in the ability of stress to further elevate alcohol consumption in subjects with a history of chronic alcohol exposure.

While stress-enhanced drinking in the CIE-FSS model has been demonstrated in both female and male mice (61,62), one limitation of this study is that only male mice were used to examine the role of DYN/KOR activity. Sex-related differences in sensitivity to DYN/KOR function have been noted, especially regarding reward and aversion/dysphoria-related behaviors (63-65). Thus, it will be important in future studies to examine whether manipulation of DYN/KOR activity within extended amygdala circuitry produces sex-related differences in stress-enhanced alcohol drinking. This is especially relevant given the high prevalence of co-occurring stress-related disorders and AUD in women (5,8).

In summary, despite stress being a significant contributing factor in heavy drinking, as reflected by high comorbidity of

stress-related disorders and AUD, few effective treatments are available, and the lack of preclinical models that reliably demonstrate stress-enhanced drinking has hindered efforts to address the problem. We have established a model demonstrating robust and highly reproducible stress-induced elevation of alcohol consumption. Using chemogenetic and pharmacological approaches, we show that DYN/KOR activity within extended amygdala circuitry plays a significant role in mediating the ability of stress to increase drinking in mice with a history of chronic alcohol exposure. These findings align with other preclinical studies showing that long-acting (20,33-35) and short-acting (36,66,67) KOR antagonists reduce high levels of alcohol consumption and relapse-like behavior provoked by stress. Together, these results support clinical studies that target the DYN/KOR system in the development of more effective treatments for individuals presenting with comorbidity of stress-related disorders and AUD (46,68).

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by the National Institutes of Health (Grant Nos. P50 AA010761 [to HCB], U01 AA 014095 [to HCB], U24 AA020929 [to MFL], R01 AA026536 [to HCB], and F31 AA0 27420 [to HLH]) and the Department of Veterans Affairs (Grant No. BLRD BX000813 [to HCB]).

We thank Ms. Olivia C. Sweatt for creating study design schematics.

The authors report no biomedical financial interests or potential conflicts of interest.

ARTICLE INFORMATION

From the Charleston Alcohol Research Center (HLH, CLL, MGS, WCG, MFL, HCB), Department of Psychiatry and Behavioral Sciences; Department of Neuroscience (HCB), Medical University of South Carolina; and the Ralph H. Johnson Department of Veterans Affairs Medical Center (HCB), Charleston, South Carolina.

Address correspondence to Howard C. Becker, Ph.D., at beckerh@musc.edu.

Received Aug 25, 2021; revised Jan 3, 2022; accepted Jan 4, 2022.

Supplementary material cited in this article is available online at <https://doi.org/10.1016/j.biopsycho.2022.01.002>.

REFERENCES

- Blaine SK, Sinha R (2017): Alcohol, stress, and glucocorticoids: From risk to dependence and relapse in alcohol use disorders. *Neuropharmacology* 122:136–147.
- Sinha R (2012): How does stress lead to risk of alcohol relapse? *Alcohol Res* 34:432–440.
- Uhart M, Wand GS (2009): Stress, alcohol and drug interaction: An update of human research. *Addict Biol* 14:43–64.
- Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, *et al.* (2015): Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. *JAMA Psychiatry* 72:757–766.
- Peltier MR, Verplaetse TL, Mineur YS, Petrakis IL, Cosgrove KP, Picciotto MR, McKee SA (2019): Sex differences in stress-related alcohol use. *Neurobiol Stress* 10:100149.
- Petrakis IL, Simpson TL (2017): Posttraumatic stress disorder and alcohol use disorder: A critical review of pharmacologic treatments. *Alcohol Clin Exp Res* 41:226–237.
- Schellekens AFA, de Jong CAJ, Buitelaar JK, Verkes RJ (2015): Comorbid anxiety disorders predict early relapse after inpatient alcohol treatment. *Eur Psychiatry* 30:128–136.
- Guinle MIB, Sinha R (2020): The role of stress, trauma, and negative affect in alcohol misuse and alcohol use disorder in women. *Alcohol Res* 40:05.
- Koob GF (2021): Drug addiction: Hyperkatifeia/negative reinforcement as a framework for medications development. *Pharmacol Rev* 73:163–201.
- Koob GF, Volkow ND (2016): Neurobiology of addiction: A neuro-circuitry analysis. *Lancet Psychiatry* 3:760–773.
- Becker HC (2017): Influence of stress associated with chronic alcohol exposure on drinking. *Neuropharmacology* 122:115–126.
- Becker HC, Lopez MF, Doremus-Fitzwater TL (2011): Effects of stress on alcohol drinking: A review of animal studies. *Psychopharmacology (Berl)* 218:131–156.
- Noori HR, Helinski S, Spanagel R (2014): Cluster and meta-analyses on factors influencing stress-induced alcohol drinking and relapse in rodents. *Addict Biol* 19:225–232.
- Spanagel R, Noori HR, Heilig M (2014): Stress and alcohol interactions: Animal studies and clinical significance. *Trends Neurosci* 37:219–227.
- Anderson RI, Lopez MF, Becker HC (2016): Forced swim stress increases ethanol consumption in C57BL/6J mice with a history of chronic intermittent ethanol exposure. *Psychopharmacology (Berl)* 233:2035–2043.
- Lopez MF, Anderson RI, Becker HC (2016): Effect of different stressors on voluntary ethanol intake in ethanol-dependent and nondependent C57BL/6J mice. *Alcohol* 51:17–23.
- Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS, Heilig MA (2008): Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala *crhr1* expression following a history of dependence. *Biol Psychiatry* 63:139–145.
- Farris SP, Tiwari GR, Ponomareva O, Lopez MF, Mayfield RD, Becker HC (2020): Transcriptome analysis of alcohol drinking in non-dependent and dependent mice following repeated cycles of forced swim stress exposure. *Brain Sci* 10:275.
- Rodberg EM, den Hartog CR, Anderson RI, Becker HC, Moorman DE, Vazey EM (2017): Stress facilitates the development of cognitive dysfunction after chronic ethanol exposure. *Alcohol Clin Exp Res* 41:1574–1583.
- Rose JH, Karkhanis AN, Chen R, Gioia D, Lopez MF, Becker HC, *et al.* (2016): Supersensitive kappa opioid receptors promotes ethanol withdrawal-related behaviors and reduce dopamine signaling in the nucleus accumbens. *Int J Neuropsychopharmacol* 19:pyv127.
- Chavkin C, Koob GF (2016): Dynorphin, dysphoria, and dependence: The stress of addiction. *Neuropsychopharmacology* 41:373–374.
- Karkhanis AN, Al-Hasani R (2020): Dynorphin and its role in alcohol use disorder. *Brain Res* 1735:146742.
- Tejeda HA, Bonci A (2019): Dynorphin/kappa-opioid receptor control of dopamine dynamics: Implications for negative affective states and psychiatric disorders. *Brain Res* 1713:91–101.
- Bruchas MR, Chavkin C (2010): Kinase cascades and ligand-directed signaling at the kappa opioid receptor. *Psychopharmacology (Berl)* 210:137–147.
- Bruchas MR, Land BB, Chavkin C (2010): The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. *Brain Res* 1314:44–55.
- Crowley NA, Kash TL (2015): Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. *Prog Neuropsychopharmacol Biol Psychiatry* 62:51–60.
- Wee S, Koob GF (2010): The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. *Psychopharmacology (Berl)* 210:121–135.
- Knoll AT, Carlezon WA Jr (2010): Dynorphin, stress, and depression. *Brain Res* 1314:56–73.
- Van't Veer A, Carlezon WA Jr (2013): Role of kappa-opioid receptors in stress and anxiety-related behavior. *Psychopharmacology (Berl)* 229:435–452.
- Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008): The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. *J Neurosci* 28:407–414.
- Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS (2004): Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. *J Neurochem* 90:1258–1268.
- Anderson RI, Becker HC (2017): Role of the dynorphin/kappa opioid receptor system in the motivational effects of ethanol. *Alcohol Clin Exp Res* 41:1402–1418.
- Walker BM, Koob GF (2008): Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. *Neuropsychopharmacology* 33:643–652.
- Walker BM, Zorrilla EP, Koob GF (2011): Systemic κ -opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. *Addict Biol* 16:116–119.
- Anderson RI, Lopez MF, Griffin WC, Haun HL, Bloodgood DW, Pati D, *et al.* (2019): Dynorphin-kappa opioid receptor activity in the central amygdala modulates binge-like alcohol drinking in mice. *Neuropsychopharmacology* 44:1084–1092.
- Anderson RI, Lopez MF, Becker HC (2016): Stress-induced enhancement of ethanol intake in C57BL/6J mice with a history of chronic ethanol exposure: Involvement of kappa opioid receptors. *Front Cell Neurosci* 10:45.
- Al-Hasani R, McCall JG, Shin G, Gomez AM, Schmitz GP, Bernardi JM, *et al.* (2015): Distinct subpopulations of nucleus accumbens dynorphin neurons drive aversion and reward. *Neuron* 87:1063–1077.
- Bloodgood DW, Hardaway JA, Stanhope CM, Pati D, Pina MM, Neira S, *et al.* (2021): Kappa opioid receptor and dynorphin signaling in the central amygdala regulates alcohol intake. *Mol Psychiatry* 26:2187–2199.
- Mansour A, Fox CA, Meng F, Akil H, Watson SJ (1994): Kappa 1 receptor mRNA distribution in the rat CNS: Comparison to kappa receptor binding and prodynorphin mRNA. *Mol Cell Neurosci* 5:124–144.
- Marchant NJ, Densmore VS, Osborne PB (2007): Coexpression of prodynorphin and corticotrophin-releasing hormone in the rat central amygdala: Evidence of two distinct endogenous opioid systems in the lateral division. *J Comp Neurol* 504:702–715.
- Poulin JF, Arbour D, Laforest S, Drolet G (2009): Neuroanatomical characterization of endogenous opioids in the bed nucleus of the stria terminalis. *Prog Neuropsychopharmacol Biol Psychiatry* 33:1356–1365.
- Erikson CM, Wei G, Walker BM (2018): Maladaptive behavioral regulation in alcohol dependence: Role of kappa-opioid receptors in the bed nucleus of the stria terminalis. *Neuropharmacology* 140:162–173.

43. Kissler JL, Sirohi S, Reis DJ, Jansen HT, Quock RM, Smith DG, Walker BM (2014): The one-two punch of alcoholism: Role of central amygdala dynorphins/kappa-opioid receptors. *Biol Psychiatry* 75:774–782.
44. Nealey KA, Smith AW, Davis SM, Smith DG, Walker BM (2011): κ -opioid receptors are implicated in the increased potency of intracumbens nalmefene in ethanol-dependent rats. *Neuropharmacology* 61:35–42.
45. Haun HL, Griffin WC, Lopez MF, Becker HC (2020): Kappa opioid receptors in the bed nucleus of the stria terminalis regulate binge-like alcohol consumption in male and female mice. *Neuropharmacology* 167:107984.
46. Reed B, Butelman ER, Kreek MJ (2022): Kappa opioid receptor antagonists as potential therapeutics for mood and substance use disorders. *Handb Exp Pharmacol* 271:473–491.
47. Krashes MJ, Shah BP, Madara JC, Olson DP, Strohlic DE, Garfield AS, *et al.* (2014): An excitatory paraventricular nucleus to AgRP neuron circuit that drives hunger. *Nature* 507:238–242.
48. Melendez RI, McGinty JF, Kalivas PW, Becker HC (2012): Brain region-specific gene expression changes after chronic intermittent ethanol exposure and early withdrawal in C57BL/6J mice. *Addict Biol* 17:351–364.
49. Solomon MG, Griffin WC, Lopez MF, Becker HC (2019): Brain regional and temporal changes in BDNF mRNA and microRNA-206 expression in mice exposed to repeated cycles of chronic intermittent ethanol and forced swim stress. *Neuroscience* 406:617–625.
50. Stamatakis AM, Sparta DR, Jennings JH, McElligott ZA, Decot H, Stuber GD (2014): Amygdala and bed nucleus of the stria terminalis circuitry: Implications for addiction-related behaviors. *Neuropharmacology* 76 Pt B:320–328.
51. Girgenti MJ, Pothula S, Newton SS (2021): Stress and its impact on the transcriptome. *Biol Psychiatry* 90:102–108.
52. Palmisano M, Pandey SC (2017): Epigenetic mechanisms of alcoholism and stress-related disorders. *Alcohol* 60:7–18.
53. Pucci M, Micioni Di Bonaventura MV, Wille-Bille A, Fernández MS, Maccarrone M, Pautassi RM, *et al.* (2019): Environmental stressors and alcoholism development: Focus on molecular targets and their epigenetic regulation. *Neurosci Biobehav Rev* 106:165–181.
54. Ferguson LB, Patil S, Moskowitz BA, Ponomarev I, Harris RA, Mayfield RD, Messing RO (2019): A pathway-based genomic approach to identify medications: Application to alcohol use disorder. *Brain Sci* 9:381.
55. Smith ML, Lopez MF, Wolen AR, Becker HC, Miles MF (2020): Brain regional gene expression network analysis identifies unique interactions between chronic ethanol exposure and consumption. *PLoS One* 15:e0233319.
56. Zhou Y, Colombo G, Gessa GL, Kreek MJ (2013): Effects of voluntary alcohol drinking on corticotropin-releasing factor and prodynorphin mRNA levels in the central amygdala of Sardinian alcohol-preferring rats. *Neurosci Lett* 554:110–114.
57. Chung S, Kim HJ, Kim HJ, Choi SH, Cho JH, Cho YH, *et al.* (2014): Desipramine and citalopram attenuate pretest swim-induced increases in prodynorphin immunoreactivity in the dorsal bed nucleus of the stria terminalis and the lateral division of the central nucleus of the amygdala in the forced swimming test. *Neuropeptides* 48: 273–280.
58. Reed B, Fang N, Mayer-Blackwell B, Chen S, Yuferov V, Zhou Y, Kreek MJ (2012): Chromatin alterations in response to forced swimming underlie increased prodynorphin transcription. *Neuroscience* 220:109–118.
59. Torruella-Suárez ML, Vandenberg JR, Cogan ES, Tipton GJ, Teklezghi A, Dange K, *et al.* (2020): Manipulations of central amygdala neurotensin neurons alter the consumption of ethanol and sweet fluids in mice. *J Neurosci* 40:632–647.
60. de Guglielmo G, Kallupi M, Pomrenze MB, Crawford E, Simpson S, Schweitzer P, *et al.* (2019): Inactivation of a CRF-dependent amygdalofugal pathway reverses addiction-like behaviors in alcohol-dependent rats. *Nat Commun* 10:1238.
61. Lopez MF, Reasons SE, Carper BA, Nolen TL, Williams RL, Becker HC (2020): Evaluation of the effect of doxazosin and zonisamide on voluntary ethanol intake in mice that experienced chronic intermittent ethanol exposure and stress. *Alcohol* 89:37–42.
62. den Hartog CR, Blandino KL, Nash ML, Sjogren ER, Grampetro MA, Moorman DE, Vazey EM (2020): Noradrenergic tone mediates marble burying behavior after chronic stress and ethanol. *Psychopharmacology (Berl)* 237:3021–3031.
63. Becker JB, Chartoff E (2019): Sex differences in neural mechanisms mediating reward and addiction. *Neuropsychopharmacology* 44:166–183.
64. Chartoff EH, Mavrikaki M (2015): Sex differences in kappa opioid receptor function and their potential impact on addiction. *Front Neurosci* 9:466.
65. Vijay A, Wang S, Worhunsky P, Zheng MQ, Nabulsi N, Ropchan J, *et al.* (2016): PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. *Am J Nucl Med Mol Imaging* 6:205–214.
66. Domi E, Barbier E, Augier E, Augier G, Gehlert D, Barchiesi R, *et al.* (2018): Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders. *Neuropsychopharmacology* 43:1805–1812.
67. Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, *et al.* (2014): LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. *Neuropharmacology* 77:131–144.
68. Lowe SL, Wong CJ, Witcher J, Gonzales CR, Dickinson GL, Bell RL, *et al.* (2014): Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa Opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects. *J Clin Pharmacol* 54:968–978.